What Is Ibutamoren? A Comprehensive MK677 Review
MK677, also known as Ibutamoren or Nutrobal, is an orally active, non-peptide human growth hormone secretagogue with a 24 hour half life. MK677 has a mechanism of action by functioning as a selective agonist of the ghrelin receptor. MK677 is frequently falsely categorized as a SARM (selective androgen receptor modulator). This false categorization is largely a result of the fitness, athlete, and bodybuilding communities and their interest in MK677 results such as fat loss, muscle growth, anti-aging benefits, improved mood, improved sleep, and more purported benefits. MK677 advantages include being an alternative to using injectable human growth hormone (HGH), or injectable GHRP and GHRH peptides. MK677 cost also offers a significant savings compared to the aforementioned peptides.
In this Ibutamoren review, we will describe MK677 (Ibutamoren/Nutrobal) effects on the body, and why there are Ibutamoren benefits when compared to human growth hormone or growth hormone releasing peptides.
Fat Loss & Muscle Growth:
One of the essential MK677 advantages that many observe is improved muscle development and fat loss. MK677 causes the pituitary to release more human growth hormone (HGH). Elevated levels of HGH lead to elevated levels of IGF-1 (
Available research and many MK677 reviews have shown that MK677 can improve sleep quality, similar to the way in which HGH can improve sleep quality. This effect can lead to improved whole body regeneration, feeling more rested, having more daytime energy, and having an improved mood.
Even those who are not interested in the MK677 research and MK677 reviews about muscle growth and fat loss, may be very interested in the research and reviews about MK677 sleep benefits.
Increased Bone Density:
MK677 bone density improvement is a benefit that research has shown to take place over time with consistent use. Since MK677 increases HGH and IGF-1 levels, over longer periods of use, these elevated endogenous peptide hormones can contribute to favorable increases in bone density.
Improved Injury Recovery:
MK677 injury repair benefits are also a result of increased levels of HGH and IGF-1. MK677 reports have suggested that users notice faster healing of injuries including joint (tendon/ligament), muscle, and other injuries.
MK677 (Ibutamoren/Nutrobal) does not require injection or reconstitution (mixing of
MK677 offers a significant cost savings when compared with high quality HGH. HGH can costs hundreds or even thousands of dollars per month, whereas MK677 will cost a fraction of that.
In this MK677 review, we will also discuss common side effects of MK677 (Ibutamoren/Nutrobal) use:
Depending on the circumstances, the increase in appetite from MK677 that many report can be viewed as favorable or unfavorable. While MK677 has shown to improve fat lass, some may find that the appetite increase causes additional calorie consumption.
MK677 water retention is reported on occasion. Some experience that the water retention fades after a short period of use as the body adapts. Water retention is also something seen with HGH, so it is not ultimately surprising that it can occur with MK677.
Where to Buy MK677?
MK677 (Ibutamoren/Nutrobal) is available from ELV Bioscience for research or laboratory use. Our research chemicals are made in an ISO9001 cGMP facility within the United States under strict purity, potency, and quality control standards.
Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ, Fisher MH, Nargund RP, Patchett AA (October 1997). “Peptidomimetic regulation of growth hormone secretion”. Endocrine Reviews. The Endocrine Society. 18 (5): 621–45. doi:10.1210/edrv.18.5.0316. PMID 9331545.http://adisinsight.springer.com/drugs/800007434
Smith RG, Thorner MO (28 January 2000). Human Growth Hormone: Research and Clinical Practice. Springer Science & Business Media. pp. 45–. ISBN 978-1-59259-015-5.
Pong SS, Chaung LY, Dean DC, Nargund RP, Patchett AA, Smith RG (January 1996). “Identification of a new G-protein-linked receptor for growth hormone secretagogues”. Molecular Endocrinology. 10 (1): 57–61. doi:10.1210/me.10.1.57. PMID 8838145.
Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G (July 1995). “Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue”. Proceedings of the National Academy of Sciences of the United States of America. 92 (15): 7001–5. doi:10.1073/pnas.92.15.7001. PMC 41459. PMID 7624358.
Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, Schwartz TW (January 2009). “Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor”. Molecular Pharmacology. 75 (1): 44–59. doi:10.1124/mol.108.049189. PMID 18923064.
Cassoni P, Papotti M, Ghè C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G (April 2001). “Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines”. The Journal of Clinical Endocrinology and Metabolism. 86 (4): 1738–45. doi:10.1210/jcem.86.4.7402. PMID 11297611.
Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, et al. (December 1996). “Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects”. The Journal of Clinical Endocrinology and Metabolism. 81 (12): 4249–57. doi:10.1210/jcem.81.12.8954023. PMID 8954023.
Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML (1997). “Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging”. Recent Progress in Hormone Research. 52: 215–44, discussion 244-6. PMID 9238854.
Copinschi G, Van Onderbergen A, L’Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E (August 1996). “Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men”. The Journal of Clinical Endocrinology and Metabolism. 81 (8): 2776–82. doi:10.1210/jcem.81.8.8768828. PMID 8768828.
Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ (March 2001). “Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women”. The Journal of Clinical Endocrinology and Metabolism. 86 (3): 1116–25. doi:10.1210/jcem.86.3.7294. PMID 11238495.
Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO (October 1997). “Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults”. The Journal of Clinical Endocrinology and Metabolism. 82 (10): 3455–63. doi:10.1210/jc.82.10.3455. PMID 9329386.
Smith RG, Sun Y, Jiang H, Albarran-Zeckler R, Timchenko N (November 2007). “Ghrelin receptor (GHS-R1A) agonists show potential as interventive agents during aging”. Annals of the New York Academy of Sciences. 1119: 147–64. doi:10.1196/annals.1404.023. PMID 18056963.
Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ (July 1999). “Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group”. Journal of Bone and Mineral Research. 14 (7): 1182–8. doi:10.1359/jbmr.19188.8.131.522. PMID 10404019.